πŸ‡ΊπŸ‡Έ FDA
Patent

US 11692032

Anti-LAG3 antibodies and uses thereof

granted A61KA61K2039/505A61K2039/507

Quick answer

US patent 11692032 (Anti-LAG3 antibodies and uses thereof) held by REGENERON PHARMACEUTICALS, INC. expires Mon Jun 29 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Jul 04 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 29 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
28
CPC classes
A61K, A61K2039/505, A61K2039/507, A61K39/3955, A61K45/06